Opinion
Volume 09:01, 2025

Hepatology and Pancreatic Science

ISSN: 2573-4563

Open Access

MASLD: Redefining Metabolic Liver Disease

Wei Zhang*

Institute of Hepatic Biology & Pancreatic Studies, Peking Central Hospital, Beijing, China

Introduction

This article details the international consensus to rename nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction–associated steatotic liver disease (MASLD)[1].

Here's the thing, the new MASLD nomenclature isn't just a name change; it's a paradigm shift that integrates metabolic risk factors directly into the diagnosis[2].

This clinical practice guideline provides comprehensive recommendations for diagnosing and managing MASLD[3].

What this really means is that moving from NAFLD to MASLD signals a crucial recognition of the disease's metabolic roots[4].

This review delves into the latest advancements in drug therapies for MASLD[5].

Let's break it down: changing the name of fatty liver disease has significant implications for how clinical trials are designed and interpreted[6].

This paper highlights the strong link between MASLD and cardiovascular disease (CVD), positioning MASLD as a significant risk factor for heart-related complications[7].

The shift in nomenclature to MASLD, METAVFLD (Metabolic-associated steatohepatitis with viral hepatitis), and cryptogenic cirrhosis marks a pivotal moment in understanding and classifying liver diseases[8].

This study provides up-to-date figures on the global prevalence of MASLD, offering critical insights into the disease burden worldwide[9].

Here's the deal: lifestyle modification remains the cornerstone of MASLD management[10].

Description

The international consensus to rename nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) represents a crucial advancement in understanding and classifying liver conditions [1]. This nomenclature shift goes beyond a simple name change; it's a paradigm shift that integrates metabolic risk factors directly into the diagnostic framework [2]. What this really means is that moving from NAFLD to MASLD signals a crucial recognition of the disease's metabolic roots, unifying understanding and encouraging a more targeted approach to prevention and treatment, especially given the global epidemic of metabolic disorders [4]. This new classification also introduces categories like MetALD for individuals with MASLD and significant alcohol intake, and cryptogenic SLD, providing a more precise classification framework for clinical practice and research [1]. The shift also includes METAVFLD (Metabolic-associated steatohepatitis with viral hepatitis) and cryptogenic cirrhosis, aiming to improve diagnostic accuracy and pave the way for more tailored therapeutic approaches by categorizing patients based on metabolic risk factors, viral co-infections, or unknown etiologies [8].

This reclassification significantly impacts clinical practice, from patient screening and diagnosis to treatment strategies [2]. MASLD is now emphasized as a multisystem disease, frequently coexisting with obesity, type 2 diabetes, and cardiovascular disease, necessitating a holistic management approach [2]. Clinical practice guidelines provide comprehensive recommendations for diagnosing and managing MASLD, offering practical advice for healthcare providers on identifying at-risk patients and using non-invasive tests for staging liver disease [3]. These guidelines stress the importance of personalized care and multidisciplinary approaches for optimal patient outcomes [3].

Regarding management, lifestyle modification remains the cornerstone of MASLD treatment [10]. Here's the deal: dietary changes, increased physical activity, and weight loss interventions have proven effective in improving liver histology and metabolic parameters. Personalized, sustainable lifestyle changes are crucial for preventing disease progression and achieving remission, often proving more impactful than pharmaceutical approaches alone [10]. Despite this, a review delves into the latest advancements in drug therapies for MASLD, surveying emerging pharmacological agents, their mechanisms of action, and their potential to address underlying metabolic dysfunctions and liver fibrosis [5]. These discussions include drugs targeting insulin resistance, lipid metabolism, inflammation, and fibrosis, offering hope for more effective treatment options beyond lifestyle interventions [5].

Changing the name of fatty liver disease has significant implications for how clinical trials are designed and interpreted [6]. This involves exploring the impact of the new MASLD nomenclature on patient enrollment criteria, study endpoints, and the overall relevance of ongoing and future trials. Harmonization in trial design is essential to accurately assess therapeutic efficacy for this redefined disease [6]. Furthermore, there's a strong link between MASLD and cardiovascular disease (CVD), positioning MASLD as a significant risk factor for heart-related complications [7]. Shared pathogenic mechanisms, like insulin resistance and chronic inflammation, contribute to both conditions, making understanding this connection crucial for screening, early intervention, and integrated management strategies to reduce overall morbidity and mortality [7]. This study also provides up-to-date figures on the global prevalence of MASLD, underscoring it as a widespread public health issue with varying prevalence rates influenced by geography, ethnicity, and metabolic risk factor distribution [9]. This data is essential for informing public health policies and resource allocation for prevention and treatment strategies worldwide [9].

Conclusion

The recent international consensus to rename nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) marks a pivotal shift in understanding liver pathologies. This new nomenclature accurately reflects the disease's metabolic underpinnings and systemic nature, incorporating metabolic risk factors directly into diagnosis. The reclassification impacts clinical practice significantly, influencing patient screening, diagnosis, and treatment strategies. MASLD is increasingly recognized as a multisystem disease, often coexisting with conditions like obesity, type 2 diabetes, and cardiovascular disease (CVD), necessitating a holistic management approach. New classifications like MetALD for those with significant alcohol intake and cryptogenic SLD provide a more precise framework for both clinical practice and research. Clinical practice guidelines offer comprehensive recommendations for managing MASLD, from identifying at-risk patients and using non-invasive tests to implementing lifestyle modifications and exploring pharmacologic therapies. Lifestyle changes, including dietary adjustments, increased physical activity, and weight loss, remain the cornerstone of effective management, often proving more impactful than drugs alone in preventing disease progression. Advances in drug therapies for MASLD are also emerging, targeting insulin resistance, lipid metabolism, inflammation, and fibrosis. The change in nomenclature also has profound implications for clinical trial design, requiring harmonization in patient enrollment criteria and study endpoints to accurately assess therapeutic efficacy. Globally, MASLD is a widespread public health concern, with prevalence varying by geography, ethnicity, and metabolic risk factors. Recognizing its strong link to CVD, with shared pathogenic mechanisms like insulin resistance and chronic inflammation, is crucial for integrated management strategies to reduce overall morbidity and mortality.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Maria E Rinella, Juergen V Lazarus, Vlad Ratziu. "Redefining Fatty Liver Disease: An International Consensus on Metabolic Dysfunction-Associated *Steatotic Liver Disease* (MASLD)." J Hepatol 79 (2023):934-943.
2. Mohamed Eslam, Shiv Kumar Sarin, Jian-Gao Fan. "Metabolic dysfunction-associated steatotic liver disease (MASLD): The new nomenclature and its impact on clinical practice." *J Hepatol* 79 (2023):847-852.
3. Fasiha Kanwal, Joseph K Lim, Mazen Noureddin. "Clinical Practice Guideline: The diagnosis and management of metabolic dysfunction-associated steatotic liver disease." *Am J Gastroenterol* 119 (2024):228-262.
4. Wataru Tomeno, Masaya Yoneda, Kento Imajo. "Metabolic dysfunction-associated steatotic liver disease: a new name for an old disease." *J Gastroenterol* 59 (2024):21-27.
5. Eunyoung Han, Ga-Hyun Kim, Sae-Mi Kim. "Recent Advances in Pharmacotherapy for Metabolic Dysfunction-Associated Steatotic Liver Disease." *Int J Mol Sci* 25 (2024):443.
6. Stephen A Harrison, Arun J Sanyal, Vincent Wai-Sun Wong. "Nomenclature change for fatty liver disease: potential implications for clinical trials." *Nat Rev Gastroenterol Hepatol* 21 (2024):122-132.
7. Zobair M Younossi, Maria E Rinella, Vincent Wai-Sun Wong. "Metabolic dysfunction-associated steatotic liver disease and its impact on the development of cardiovascular disease." *J Hepatol* 79 (2023):1475-1486.
8. Naga Chalasani, Zobair Younossi, Omar Massoud. "A new era in fatty liver disease: The nomenclature for MASLD, METAVFLD, and cryptogenic cirrhosis." *Clin Liver Dis* 28 (2024):1-13.
9. Jia J Quek, Phyllis Tay, Charlene Mah. "Global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)." *Clin Mol Hepatol* 30 (2024):13-21.
10. Giovanni Targher, Christopher D Byrne, Vincent Wai-Sun Wong. "Lifestyle modification in the management of metabolic dysfunction-associated steatotic liver disease." *Nat Rev Gastroenterol Hepatol* 21 (2024):5-19.

How to cite this article: Zhang, Wei. "MASLD: Redefining Metabolic Liver Diseaes." *J Hepatol Pancreat Sci* 09 (2025):317.

Address for Correspondence: Wei, Zhang, Institute of Hepatic Biology & Pancreatic Studies, Peking Central Hospital, Beijing, China, E-mail: weizhang@pchospital.cn

Received: 01-Jan-2025, Manuscript No. hps-25-789458; **Editor assigned:** 03-Jan-2025, PreQC No. P-172031; **Reviewed:** 17-Jan-2025, QC No. Q-789458; **Revised:** 22-Jan-2025, Manuscript No. R-172031; **Published:** 29-Jan-2025, DOI: 10.37421/2573-4563.2024.9.317